Dyslipidemia is a serious threat to human health.The objective of our research was to develop effective FXR antagonists against dyslipidemia.Herein we describe the design, synthesis of 37 N-(5-(2,5-dimethylphenoxy)-2,2- dimethylpentyl)-benzamide derivatives and evaluated for their FXR inhibition ability compared to GS and SIPI-7623.Structure-activity relationship analyses indicated that compounds containing hydroxyl on the right side of the Ph were more effective than those without hydroxyl.Compound BI-24 was identified to have the most potent antagonic activity with an IC50 value of 10.8μM for FXR, exhibited no cytotoxicity on HepG2 cells and reduced levels of TC, TG, LDL-C for 36%, 69%, and 32% on serum, resp.Compound BI-24 may be developed to a potential agent for the treatment of dyslipidemia.